3 Swedish Growth Stocks With Insider Ownership As High As 35%
In This Article:
In recent weeks, the European markets have experienced notable declines amid renewed fears about global economic growth, with Sweden's market also feeling the pressure. Despite these challenges, some Swedish growth companies stand out due to their high insider ownership, which can be a strong indicator of confidence in their long-term potential. Investors often look for stocks where insiders hold significant shares as it suggests that those with the most knowledge and insight into the company believe in its future success. In light of current market uncertainties, such insider confidence can provide an added layer of reassurance for potential investors.
Top 10 Growth Companies With High Insider Ownership In Sweden
| Name | Insider Ownership | Earnings Growth |
| CTT Systems (OM:CTT) | 16.9% | 24.8% |
| Truecaller (OM:TRUE B) | 29.5% | 21.6% |
| Fortnox (OM:FNOX) | 21.1% | 22.6% |
| Magle Chemoswed Holding (OM:MAGLE) | 14.9% | 72.2% |
| Biovica International (OM:BIOVIC B) | 18.8% | 73.1% |
| BioArctic (OM:BIOA B) | 34% | 98.4% |
| Yubico (OM:YUBICO) | 37.5% | 42.5% |
| KebNi (OM:KEBNI B) | 37.8% | 86.1% |
| InCoax Networks (OM:INCOAX) | 19.3% | 115.5% |
| OrganoClick (OM:ORGC) | 23.1% | 109.0% |
Here we highlight a subset of our preferred stocks from the screener.
BioArctic
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (publ) develops biological drugs for central nervous system disorders in Sweden and has a market cap of SEK 16.08 billion.
Operations: BioArctic's revenue from biotechnology amounts to SEK 299.35 million.
Insider Ownership: 34%
BioArctic, a Swedish growth company with high insider ownership, has shown significant progress in recent months. The company's Q2 2024 earnings report revealed a substantial increase in sales to SEK 49.84 million from SEK 2.71 million the previous year, though it still posted a net loss of SEK 68.43 million. Recent product developments include promising phase-1 study results for exidavnemab and regulatory approval for Leqembi? in multiple countries, enhancing its Alzheimer's treatment portfolio. Despite high volatility and current losses, analysts forecast strong revenue growth (42.4% per year) and profitability within three years, positioning BioArctic as a potentially valuable investment opportunity in Sweden's biotech sector.
-
Take a closer look at BioArctic's potential here in our earnings growth report.
-
Our expertly prepared valuation report BioArctic implies its share price may be lower than expected.
Medicover
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Medicover AB (publ) operates healthcare and diagnostic services in Poland, Sweden, and internationally, with a market cap of SEK28.38 billion.